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Abstract
Background: H1N1 influenza A virus infections were first reported in April 2009 and spread rapidly, resulting in mortality 
worldwide. The aim of  this study was to evaluate patients with H1N1 infection treated in the intensive care unit (ICU) in 
Bursa, Turkey. 
Methods: Demographic characteristics, clinical features, and outcome relating to H1N1 infection were retrospectively ana-
lysed in patients treated in the ICU.
Results: Twenty-three cases of  H1N1 infection were treated in the ICU. The mean age of  patients was 37 years  range: (17–
82). Fifteen patients were female (65.2%). The mean Acute Physiology and Chronic Health Evaluation (APACHE) II score 
was 19 range: (5–39). The most common symptoms were dyspnea (73.9%), fever (69.6%), and cough (60.9%). Mechanical 
ventilation was required for all patients. Oseltamivir and antibiotics were administered to all patients. Six (26.1%) patients 
died. APACHE II scores were higher in the deceased 28.5 range: [16–39] vs. 14 range: [5–28] in survivors; p = 0.013). 
Conclusion: When compared to the literature, the demographic, epidemiological, and clinical characteristics were similar 
in the cases we encountered. The mortality rate was high despite the use of  appropriate treatment. We believe that the high 
mortality is related to higher APACHE II scores. The H1N1 virus should be considered in community acquired pneumonia, 
especially in younger patients presenting with severe pneumonia.
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Introduction
In 2009, millions of  people worldwide were affected by 
the rapid person-to-person spread of  the H1N1 influ-
enza A virus1,2. In June 2009, the World Health Organ-
isation (WHO) declared a level 6 warning for this new 
influenza pandemic3. 
The H1N1 virus spread aggressively in Turkey dur-
ing October 2009–January 2010, reaching a peak dur-
ing weeks 46–47 of  20094. During the second half  of  
2009, influenza cases were seen in to the city of  Bursa. 
The first patient was admitted to the pulmonology de-
partment of  Uludag University Hospital on the 12th of  
November 2009, and then admitted to our ICU on the 
15th of  November 2009 as the first critically ill patient 
with respiratory failure due to H1N1 infection. Uludag 
University Hospital is the only tertiary care centre es-
tablished by the government in Bursa, and is also the 
major reference centre for the southern Marmara re-
gion. Bursa is the fourth largest city in Turkey, with a 
population of  approximately 2 million residents. 
As the first pandemic of  the 21st century, this infection 
primarily affected those with underlying respiratory and 
cardiac disease, children, young adults, and pregnant 
women2,5,6. Although early symptoms similar to season-
al influenza were observed, cases of  H1N1 infection 
progressed to viral pneumonia, respiratory failure, hy-
poxia, and organ failure resulting in death6-8. Some cases 
were treated in the ICU, and mortality was reported to 
be 5%–50%7-12.
This retrospective study describes the demographic 
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characteristics, clinical features, and outcome of  adult 
patients with severe H1N1 virus infection who were 
treated in the ICU for respiratory failure from Novem-
ber 2009 to February 2010.
Methods
The study was approved by the Hospital Ethics Com-
mittee. A retrospective analysis of  patients diagnosed 
with H1N1 influenza A infection who were treated in 
the ICU of  Uludag University Hospital in Bursa, Tur-
key, during November 2009 to February 2010 was car-
ried out.
Features of  the ICU and the hospital 
The ICU of  Uludag University Hospital’s Anesthesiolo-
gy Department is a 19-bed mixed (surgical and medical) 
unit that cares exclusively for adult patients. There are a 
total of  6 doctors (3 senior consultants and 3 anaesthe-
siology residents) caring for the patients. Additionally, a 
senior consultant from the Infectious Diseases Depart-
ment examines the patients on a daily basis. Admission 
to the unit is based on many indications, including acute 
respiratory failure requiring invasive/non-invasive me-
chanical ventilation, which is relevant to this study. 
Patients and assessment
Data related to the epidemiology of  the cases and the 
treatment process were considered. A record was made 
of  age, gender, presence of  co-morbidity, pregnancy 
or childbirth within the previous 28 days, initial symp-
toms, and time from reporting of  the initial symptoms 
to admittance to the ICU and evaluation of  APACHE 
II scores. Individuals with a body mass index (BMI) of  
30–40 were classified as obese, whereas those with a 
BMI >40 were considered as morbidly obese.
An examination was made of  the pulmonary radio-
graphic findings collected during each patient’s ICU stay; 
PaO2/FiO2 ratios, laboratory parameters (leucocytes, 
thrombocytes, urea, creatinine, aspartate aminotransam-
inase, alanine aminotransaminase), treatments applied 
during hospitalisation (invasive mechanical ventilation 
[IMV], non-invasive mechanical ventilation [NIMV], 
antiviral therapy, antibiotherapy and corticosteroids), 
virological validation results, duration of  ICU stay, and 
mortality were evaluated. 
Statistical analysis
Statistical analysis was carried out using SPSS 13.0 (Sta-
tistical Package for Social Sciences). The conformity of  
the variables to normal distribution was examined using 
the Shapiro–Wilk test. Continuous and discrete varia-
bles were expressed as median values (minimum-maxi-
mum). The Mann-Whitney U, Pearson Chi-Square, and 
Fisher exact chi-square tests were used in the compari-
son of  variables between groups. Categorical variables 
were expressed numerically and as percentages. The risk 
factors affecting mortality were analysed with logistic 
regression analysis. A value of  p < 0.05 was accepted as 
statistically significant.
Results
During the study period, 23 patients with a diagnosis 
of  H1N1 infection were treated in the ICU. All patients 
who were suspected to have contracted H1N1 were ad-
mitted to the ICU based on the WHO case definitions13. 
A respiratory sample was obtained for virological vali-
dation from all patients, and polymerase chain reaction 
testing was performed. 
The mean age of  the patients was 37 years (17–82 years). 
Fifteen patients were female (65.2%) and 8 were male 
(34.8%). There were 4 pregnant women and 1 post-
partum patient. The 4 pregnant women gave birth by 
Caesarean section during the treatment period. Twelve 
(52.2%) patients were admitted directly to the ICU from 
the emergency room, 6 (26.1%) from the hospital clin-
ics, and 5 (21.7%) were transferred from surrounding 
hospitals. The demographic characteristics and co-mor-
bidities of  the cases are summarised in Table 1.
The 2 most frequent symptoms were dyspnoea (73.9%) 
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and fever (69.6%) (Table 1). The time period from the 
onset of  symptoms to ICU admittance was a mean of  
5 days (1–21 days). In 14 cases of  radiologically con-
firmed pneumonia, the mean PaO2/FiO2 ratio was 
64.5 (46.5–198). There was no statistically significant 
difference between the surviving patients and the de-
ceased patients in terms of  pulmonary radiographic 
findings, mean PaO2/FiO2 ratios, and laboratory pa-
rameters (Table 2).
No bacterial agents known to cause pneumonia were 
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found in the routine cultures from endotracheal aspi-
rate samples. All patients received oseltamivir (150–300 
mg/day for 10 days) and antibiotherapy. In addition, 
10 (43.5%) patients received corticosteroids (Table 3). 
IMV was administered to 18 (78.3%) patients (12 cases 
[52.2%] with IMV only, and 6 patients [26.1%] with a 
transition from NIMV to IMV) for a mean of  8 days 
(range 4–16 days). The other 5 (21.7%) patients were 
supported with NIMV only (Table 3). 
The mean duration of  stay in the ICU was 14 days (4–
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Table 1. Demographic characteristics and co-morbidities of the patients with influenza 
A (H1N1) virus  
Variable (n = 23) 
Age, median (range) 37 (17-82) 
Female sex (n) (%) 15 (65.2) 
APACHE II score,  median (range) 19 (5-39) 
BMI, median (range) 26.9 (13-42)  
Comorbidity (n)   
     Asthma 2 
     Diabetes  1 
     Hypertension 1 
     Congestive heart failure  1 
     Alzheimer Disease 1 
     Malignancy 1 
     Cerebral palsy 1 
     Sleep apnea syndrome 1 
     Morbid obesity  1 
     Pregnancy+postpartum  4+1 
Signs and symptoms* (n) (%)  
     Dyspnea 17 (73.9) 
     Fever 16 (69.6) 
     Cough 14 (60.9) 
     Myalgias 5 (21.7) 
     Sore throat 3 (13) 
     Rhinorrhea 2 (8.7) 
     Skin eruption 1 (4.3) 
     Nausea/vomiting  1 (4.3) 
     Subconjunctival hemorrhage 1 (4.3) 




ICU lenght of stay, median (range) 14 (4-119) 
ICU mortality, (n) (%) 6 (26.1) 
APACHE: Acute Physiology and Chronic Health Evaluation,  
BMI: Body Mass Index, ICU: Intensive Care Unit 
* The patients have more than one symptom.     
Table 2. Radiographic findings, oxygenation and laboratory data of the patients with 
influenza A (H1N1) virus 









    
No infiltration  (n) (%) 9 (%39.1) 8  1 
0.480 
Unilateral infiltration  
(n) (%) 
10 (%43.5) 6  4 
Bilateral infiltration  
(n) (%) 
4 (%17.4) 3 1 
Oxygenation  
median (range) 
    
PAO2/FiO2 64 .5 (46.5-198)  66.5 (46.5-198) 60.6 (51-90.2) 0.431 
 Laboratory data 
median (range) 
    














Urea (mg/dl)  25 (9-151) 25 (9-151) 39.5 (17-119) 0.759 
Creatinine (mg/dl)  0.8 (0.5-2.9) 0.8 (0.5-2.9) 0.75 (0.5-1.9) 0.919 
AST (IU)  43 (14-767) 43 (14-767) 68 (24-179) 0.865 
ALT (IU)  24 (10-453) 23 (10-453) 25 (10-73) 0.708 
WBC: White blood cell. AST: Aspartate aminotransferase, ALT: Alanine aminotransferase.   
 
Table 3: Characteristics of treatments of the patients with influenza A (H1N1) virus 







NIMV (n) (%)  12 (52.2) 7 (41.2) 5 (83.3) 0.155 
IMV (n) (%) 6 (26.1) 6 (35.3) 0 (0) 0.144 
NIMV+IMV (n) (%) 5 (21.7) 4 (23.5) 1 (16.7) 1.000 
Duration of IMV (day), median (range) 
  
10 (0-119) 6 (0-43) 16.5 (3-119) 0.135 
Duration of NIMV (day),  median 
(range)  
0 (0-5) 1 (0-5) 0 (0-3) 0.177 
Days from onset of symptoms to first 
oseltamivir dose, median (range) 
4 (1-22) 4 (1-22) 4 (2-6) 0.562 
Days from onset of symptoms to first 
antibiotic dose, median (range) 
5 (1-22) 6 (1-22) 4 (2-6) 0.431 
Duration of antibiotic use, median 
(range)   
5 (1-22) 6 (1-22) 4 (2-6) 0.431 
Days from onset of symptoms to steroid 
median (range)   
0 (0-23) 0 (0-23) 5 (0-8) 0.431 
IMV: Invasive mechanical ventilation 
NIMV: Noninvasive mechanical ventilation 
119) for all patients. At the end of  the treatment, 17 
patients (73.9) survived, and 6 (26.1%) patients died. 
The mean length of  stay in the ICU for surviving pa-
tients and deceased patients was 14 days (4–62) and 
16.5 days (4–119), respectively. No significant differ-
ence was found between the 2 groups in terms of  the 
length of  stay in the ICU. The APACHE II scores of  
the deceased patients (28.5 [16–39]) were higher than 
those of  the survivors (14 [5–28]; p = 0.013) (Table 4). 
Seven (30.4%) patients had a BMI >30, all of  whom 
were discharged with medication. None of  the obese 
patients died. 
No statistically significant difference was observed in 
terms of  demographic and laboratory data between 
those who received corticosteroids and those who did 
not. Corticosteroid use also had no effect on survival. 
When risk factors affecting mortality were examined 
with logistic regression analysis, co-morbidity was 
found to be a factor that influenced patient mortality 
(p = 1.000). The variables of  the APACHE II score 
(p = 0.999), laboratory values (leucocytes, p = 0.997; 
thrombocytes, p = 0.997; urea, p = 0.999; creatinine, p 
= 1.000; aspartate aminotransferase,   p = 0.995; alanine 
aminotransferase, p = 0.998), pulmonary radiograph 
findings (p =0.994), steroid use (p = 0.997), and the 
length of  ICU stay (p = 0.998) were not found to be 
significant (logistic model significance, p = 0.009).
Discussion
We conducted a retrospective study of  cases with severe 
H1N1 virus infection who were treated in the ICU for 
respiratory failure from November 2009 to February 
2010. We  aimed to describe the demographic charac-
teristics, clinical features, and outcome of  adult patients 
with this condition.
The cases examined in this study represent a population 
affected by a pandemic. Patients infected with pandem-
ic H1N1 influenza A virus were determined to be of  
a younger age than patients infected with the seasonal 
influenza virus. It has been suggested that patients >60 
years of  age may be immune to the H1N1 virus or pre-
vious infection with influenza virus which has similar 
antigenic structures9,14,15. Nin et al.9 reported that only 
7% of  patients diagnosed with H1N1 infection and ad-
mitted to the ICU were >65 years of  age. Other studies 
that have reported the patient age to be 27–44 years 
support this finding6,7,11,12,15,16. Our data also confirmed 
that the majority of  patients infected with H1N1 were 
young adults. 
The majority of  the patients with H1N1 infection 
had a risk factor such as a co-morbidity or were preg-
nant5,6,8,9,12,14-17. In the current study, 60.9% of  cases had 
an accompanying risk factor, which is a similar finding 
in previously mentioned studies. In addition to chron-
ic disease and immunosuppression, the risk of  H1N1 
influenza infection increases during pregnancy2,5,18-21. 
In a study of  pregnant women with serious influenza 
infection conducted in Australia, the relative risks of  
hospitalisation, admittance to ICU, and death were de-
termined to be 5.2, 6.5, and 1.4, respectively23. Louie et 
al.15 reported that of  the 20% of  hospitalised pregnant 
women requiring admittance to ICU, the majority were 
in the second or third trimester. In the current study, 
4 pregnant women and 1 postpartum patient were ad-
mitted to the ICU. During the treatment period, all 4 
infants were delivered by Caesarean section. At the end 
of  the treatment, 1 patient died. 
Obesity is a newly defined risk factor that may have 
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contributed to the mortality in the 2009 H1N1 Influ-
enza A pandemic3,10,22,23. As obesity rates are high in se-
vere H1N1 cases requiring ICU treatment, and obesity 
creates a risk for H1N1 infection, researchers have sug-
gested that it may be diabetes mellitus and cardiovascu-
lar diseases together with obesity that increase the risk 
of  mortality2,23,24. Although obesity has been defined as 
a risk for the development of  pneumonia, there are re-
searchers who do not agree with this assessment8. In 
the current study, 7 patients had a BMI >30 and all were 
alive at the end of  the treatment. 
The symptoms of  H1N1 infection are similar to those 
of  seasonal influenza (high temperature, cough, sore 
throat, runny nose, headache, and myalgia)2,7,10,16,17,25. In 
a study by Perez-Padilla et al.26, the most frequently seen 
symptoms were reported to be fever, cough, and oth-
er respiratory problems. Kumar et al.8 determined that 
the most common symptoms were those affecting the 
respiratory system, weakness, and muscle pain. In the 
current study, the most frequently seen symptoms were 
cough, fever, and dyspnea.
Previous studies of  H1N1 infected patients with acute 
respiratory symptoms have shown infiltration rates of  
31.8%–100% based on pulmonary radiographs8,9,24. In 
the current study, although all the patients were ad-
mitted to ICU with respiratory problems, 60.9% were 
determined to have unilateral or bilateral infiltrations. 
There were no significant findings related to the pul-
monary radiograph screens of  the remaining patients 
(39.1%) during hospitalisation.
The use of  neuroaminidase inhibitors is recommend-
ed in cases of  proven or suspected H1N1 infection3. A 
study by Louie et al.15 reported starting antiviral treat-
ment within 48 hours of  the onset of  symptoms. Poep-
pl et al.2 reported the use of  oseltamivir in 70.8% and 
Dawood et al.27 in 74% of  cases. Oseltamivir was used 
in all cases in the current study. This was because of  the 
outbreak reaching our country later than other coun-
tries and the availability of  results from published med-
ical articles relating to the effectiveness of  this antiviral 
agent. While the duration from the onset of  symptoms 
to starting treatment was reported as 1.5 days by Louie 
et al.15, this period was 4 days in the current study. This 
delay may be due to late presentation at the hospital by 
patients following the onset of  symptoms.
In addition to antiviral therapy, antibiotherapy has been 
widely applied to cases of  H1N1 infection8,14,28. Jain et 
al.14 determined that 79% of  patients presenting at the 
hospital received antibiotherapy and of  these patients, 
70% used more than one antibiotic. In that study, it was 
reported that 3 days passed from the onset of  symp-
toms to presentation at a hospital. Kumar et al.8 report-
ed a rate of  98.8% for antibiotherapy in cases treated 
for H1N1 infection in the ICU, with a period of  5 days 
from the onset of  symptoms to admittance to ICU. 
In the current study, as the period from the onset of  
symptoms to admittance was determined to be 5 days, 
antibiotherapy was applied to all cases to cover all typi-
cal and atypical pneumonia agents.
The use of  corticosteroids for the treatment of  crit-
ical cases with H1N1 infection in the ICU has come 
into practice2,8,17,29-31. In cases of  respiratory impairment 
associated with serious H1N1 infection, corticosteroid 
use has been reported as 51%–69%7,8. While some re-
searchers have administered corticosteroids to patients 
with co-morbidities such as chronic obstructive pul-
monary disease and asthma17, others have administered 
corticosteroids in the early stages of  infection to all pa-
tients admitted to the ICU with H1N1 infection30. It 
has been suggested that the early stage administration 
of  corticosteroids has not improved prognosis27 and 
has even increased the risk of  superinfection30. In the 
current study, a dosage of  1 mg/kg of  methylpredniso-
lone was administered to 10 (43.5%) patients, and the 
use of  corticosteroids was determined to have had no 
effect on mortality.
Limitation. 
Firstly, the study was conducted retrospectively. Sec-
ondly, because the patients examined in the studies were 
limited to those in our centre only, the sample size was 




When compared to reports in the literature, the demo-
graphic, epidemiological, and clinical characteristics of  
the patients in those studies were similar to the patients 
in our study. Patient mortality was high despite the use 
of  appropriate antiviral and antibiotic treatment. We 
believe that the high mortality rate may be related to the 
higher APACHE II scores during admission to the ICU, 
and to the delayed antiviral treatment and mechanical 
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Table 4. Characteristics of the patients with influenza A (H1N1) virus  







Age, median (range) 37 (17-82) 37(17-81) 35.5(25-82) 0.812 
Female sex (n) (%) 15 (65.2) 12(70.6) 3(50) 0.621 
APACHE II score,  median (range) 19 (5-39) 14(5-28) 28.5(16-39) 0.013 
Days from onset of symptoms to ICU 
admission,   median (range) 5 (1-21) 6(1-21) 4(2-7) 0.473 
ICU lenght of stay, median (range) 14 (4-119) 14(4-62) 16.5(4-119) 0.812 
APACHE: Acute Physiology and Chronic Health Evaluation,  
ICU: Intensive Care Unit 
ventilation support due to late admission to hospital. 
The pandemic influenza A H1N1 virus should be con-
sidered in the differentiation of  community-acquired 
pneumonia, especially in younger patients presenting 
with severe pneumonia and who need mechanical ven-
tilation. 
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